OncologyEducation· @OncEd · X·· 16 小时前评分70
正文 · 机器翻译
Andrew Redfern, MD 解读 CCTG MA.40/FINER：在既往接受 CDK4/6 抑制剂治疗后，ipatasertib + fulvestrant 维持了 PFS 获益，但未改善 ER+/HER2− mBC 的 OS。#ESMO26
立即观看：https://bit.ly/4skqDBu
11 浏览 · 0 赞 · 0 转发 · 0 回复
会议摘要
LBA14按 Proffered paper 2: Breast cancer, early and advanced stage 对上
A double-blind placebo controlled randomized phase III trial of fulvestrant and ipatasertib as treatment for HER-2 negative and estrogen receptor positive (ER+) metastatic breast cancer (MBC): Overall survival results of the CCTG/BCT MA.40/
https://esmocongress.esmo.org来源：OncologyEducation · x.com